Imbioray
Hangzhou
About Imbioray
Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $74.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2026)
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/imbioray-54677 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.